Evidence Hub

Electrochemical Analysis of Favipiravir Using a Cu2O@MnO2-Modified Sensor for Drug Quality Testing

Nuenghathai Chaiya, Chochanon Moonla, Suphaporn Chenkhuruthum, anchana preechaworapun, Phetlada Kunthadee, Tanin Tangkuaram

Journal of the Electrochemical Society, 2025

Abstract

Antiviral drugs are crucial for treating various viral infections, including SARS-CoV-2, the causative agent of COVID-19. Favipiravir (FAV) is among the widely used antiviral drugs due to its efficacy against multiple viruses. However, concerns regarding drug adulteration and substandard drug quality emphasize the need for robust detection methods. This study presents the development of an electrochemical sensor for FAV determination, utilizing copper (I) oxide at manganese (IV) oxide (Cu2O@MnO2) in a chitosan scaffold, modified on a glassy carbon electrode (GCE). Under optimized conditions, the sensor demonstrated linear response from 1–200 μM with a detection limit of 0.51 μM FAV. It exhibited high selectivity with no interference from glucose, sucrose, ascorbic acid, cholesterol, molnupiravir, Cl-, CO32-, and NO3-. Repeatability and reproducibility were satisfactory, with relative standard deviations of 4.49% and 4.75% (n=5), respectively. This sensor was successfully applied to FAV tablet analysis, achieving percent recoveries ranging from 96.06 to 99.23%. Furthermore, validation against the standard method showed no significant differences in FAV analysis results, confirming the reliability of this approach.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free